^
Association details:
| Biomarker: | PIK3CA mutation + ESR1 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.
Published date:
05/25/2023
Excerpt:
The incidence of co-PIK3CA and ESR1 mutations in this predominantly Hispanic patient population was consistent with previously reported literature. We identified a trend towards worse OS and shorter duration on treatment with alpelisib + ET in the co-mutation group as compared to the PIK3CA alone group.
DOI:
10.1200/JCO.2023.41.16_suppl.e13068
